Aethlon (AEMD) has disclosed a new risk, in the Accounting & Financial Operations category.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Aethlon faces a multitude of challenges that could impede its growth and financial stability. The company has a history of significant losses and anticipates continued financial struggles, necessitating further financing that may dilute current shareholders. Furthermore, Aethlon’s limited experience with large-scale contracts and compliance with manufacturing practices, coupled with competitive pressures and potential obsolescence of its Hemopurifier technology, pose significant operational risks. Regulatory hurdles, potential delisting from Nasdaq, and difficulties in attracting executive talent further compound the risks, making investment in Aethlon’s securities speculative.
Overall, Wall Street has a Moderate Buy consensus rating on AEMD stock based on 1 Buy and 1 Hold.
To learn more about Aethlon’s risk factors, click here.
